[go: up one dir, main page]

FR2814368B1 - Preparation pharmaceutique a base d'oxans - Google Patents

Preparation pharmaceutique a base d'oxans

Info

Publication number
FR2814368B1
FR2814368B1 FR0012197A FR0012197A FR2814368B1 FR 2814368 B1 FR2814368 B1 FR 2814368B1 FR 0012197 A FR0012197 A FR 0012197A FR 0012197 A FR0012197 A FR 0012197A FR 2814368 B1 FR2814368 B1 FR 2814368B1
Authority
FR
France
Prior art keywords
oxans
pharmaceutical preparation
preparation based
pharmaceutical
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0012197A
Other languages
English (en)
Other versions
FR2814368A1 (fr
Inventor
Joel Bougaret
Laurent Liorzou
Michel Sournac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0012197A priority Critical patent/FR2814368B1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to US10/381,801 priority patent/US20040022834A1/en
Priority to CA002424949A priority patent/CA2424949A1/fr
Priority to PCT/FR2001/002980 priority patent/WO2002026216A1/fr
Priority to AU2001292001A priority patent/AU2001292001A1/en
Priority to JP2002530046A priority patent/JP2004509916A/ja
Priority to EP01972214A priority patent/EP1322298A1/fr
Publication of FR2814368A1 publication Critical patent/FR2814368A1/fr
Application granted granted Critical
Publication of FR2814368B1 publication Critical patent/FR2814368B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR0012197A 2000-09-26 2000-09-26 Preparation pharmaceutique a base d'oxans Expired - Fee Related FR2814368B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0012197A FR2814368B1 (fr) 2000-09-26 2000-09-26 Preparation pharmaceutique a base d'oxans
CA002424949A CA2424949A1 (fr) 2000-09-26 2001-09-26 Preparation pharmaceutique a base d'oxans
PCT/FR2001/002980 WO2002026216A1 (fr) 2000-09-26 2001-09-26 Preparation pharmaceutique a base d'oxans
AU2001292001A AU2001292001A1 (en) 2000-09-26 2001-09-26 Pharmaceutical oxan preparation
US10/381,801 US20040022834A1 (en) 2000-09-26 2001-09-26 Pharmaceutical oxan preparation
JP2002530046A JP2004509916A (ja) 2000-09-26 2001-09-26 オキサンに基づく薬剤
EP01972214A EP1322298A1 (fr) 2000-09-26 2001-09-26 Preparation pharmaceutique a base d'oxans

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0012197A FR2814368B1 (fr) 2000-09-26 2000-09-26 Preparation pharmaceutique a base d'oxans

Publications (2)

Publication Number Publication Date
FR2814368A1 FR2814368A1 (fr) 2002-03-29
FR2814368B1 true FR2814368B1 (fr) 2004-05-07

Family

ID=8854662

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0012197A Expired - Fee Related FR2814368B1 (fr) 2000-09-26 2000-09-26 Preparation pharmaceutique a base d'oxans

Country Status (7)

Country Link
US (1) US20040022834A1 (fr)
EP (1) EP1322298A1 (fr)
JP (1) JP2004509916A (fr)
AU (1) AU2001292001A1 (fr)
CA (1) CA2424949A1 (fr)
FR (1) FR2814368B1 (fr)
WO (1) WO2002026216A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
ES2466647T3 (es) * 2006-05-08 2014-06-10 Teikoku Seiyaku Co., Ltd. Preparación absorbible por vía transdérmica que comprende un agente contra la demencia
JP6654365B2 (ja) * 2015-06-17 2020-02-26 日東電工株式会社 貼付製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698789B1 (fr) * 1992-12-07 1995-03-03 Pf Medicament Utilisation de l'idazoxan et ses dérivés pour la préparation d'un médicament destiné au traitement de la maladie de Parkinson et de son évolution.
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
FR2706303B1 (fr) * 1993-06-18 1995-09-08 Pf Medicament Utilisation de l'Efaroxan et de ses dérivés pour la préparation d'un médicament destiné au traitement de la maladie de Parkinson.
US5635204A (en) * 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
US5879701A (en) * 1997-02-28 1999-03-09 Cygnus, Inc. Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents
FR2801786B1 (fr) * 1999-12-01 2002-03-01 Fabre Pierre Cosmetique Nouvelles compositions topiques a base d'idazoxan et de cafeine ou de ses derives solubles et leur utilisation comme amincissant et/ou dans le traitement de la cellulite

Also Published As

Publication number Publication date
US20040022834A1 (en) 2004-02-05
WO2002026216A1 (fr) 2002-04-04
WO2002026216A8 (fr) 2003-01-16
CA2424949A1 (fr) 2002-04-04
JP2004509916A (ja) 2004-04-02
AU2001292001A1 (en) 2002-04-08
FR2814368A1 (fr) 2002-03-29
EP1322298A1 (fr) 2003-07-02

Similar Documents

Publication Publication Date Title
IT1313549B1 (it) Formulazioni farmaceutiche a base di epotilone 3
PT984773E (pt) Formulacao farmaceutica a base de omeprazole
EE200200097A (et) Bensamiididerivaati sisaldav farmatseutiline preparaat
EP1427407A4 (fr) Conjugues a base d'amines gras et d'agents pharmaceutiques
ATE359064T1 (de) Pharmazeutische tramadolsalze
ATE432707T1 (de) Pharmazeutische zubereitung
FR2793061B1 (fr) Panneau d'affichage
ECSP045162A (es) "composiciones farmaceuticas a base de derivados de azetidina"
IT1313579B1 (it) Composizione farmaceutica liquida a base di paracetamolo.
EE9900545A (et) Farmatseutiline kompositsioon
FI5176U1 (fi) Sitalopraamia sisältävä farmaseuttinen koostumus
IT1283029B1 (it) Composizioni farmaceutiche a base di diclofenac
EE05331B1 (et) Bensamiididerivaati sisaldav farmatseutiline preparaat
PT1037652E (pt) Composicoes farmaceuticas a base de dalfopristina e de quinupristina e sua preparacao
PT1272499E (pt) Composicoes farmaceuticas contendo oligossacaridos e a sua preparacao
EP1397884A4 (fr) Schema de signature a base d'anneaux
FR2814368B1 (fr) Preparation pharmaceutique a base d'oxans
FR2809003B1 (fr) Compositions anti-pollution a base d'anthocyanes
EP1295601A4 (fr) Composition pharmaceutique a base d'un compose anti-inflammatoire non steroide
FR2780725B1 (fr) Fertilisant a base d'hydroretenteur(s)
FR2808731B1 (fr) Caractere d'estampage a poincon ameliore
FR2790954B1 (fr) Composition pharmaceutique a base de composes polyaromatiques
FR2791889B1 (fr) Suspension pharmaceutique buvable d'ibuprofene
SE9800251D0 (sv) A novel pharmaceutical preparation
FR2815159B1 (fr) Panneau d'affichage

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20080531